Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Animal Bites : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Cellulitis




Patient Education
Bacterial and Viral Infections Center

Rabies Overview

Rabies Causes

Rabies Symptoms

Rabies Treatment




Author: Joel Schlessinger, MD, Consulting Staff, Dermatology, Skin Specialists, PC

Joel Schlessinger is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, and Phi Beta Kappa

Editors: Neil Shear, MD, Professor and Chief of Dermatology, Professor of Medicine, Pediatrics and Pharmacology, University of Toronto Medical School; Head of Dermatology, Sunnybrook Women's College Health Sciences Center, Canada; Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center; Paul Krusinski, MD, Director of Dermatology, Professor, Department of Internal Medicine, Fletcher Allen Health Care, University of Vermont; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center

Author and Editor Disclosure

Synonyms and related keywords: dog bites, cat bites, rabies, snakebites, hand bites

Background

Animal bites are common, with more than 4.7 million people (almost 2% of the population) in the United States affected each year, according to the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. Typically, these are dog or cat bites, with the patient's age most commonly being 7-9 years, but persons of any age can be affected. Typically, the aggressor is a dog, such as a collie, a boxer, or a German shepherd. Other animal bites include bites caused by small animals, such as rabbits, ferrets, monkeys, and farm animals.

Certain breeds of animals tend to be more dangerous, and, based on a recent study by the CDC, Allstate Insurance Company comprised a list of 8 dogs they won't insure against bites. On the list are Akitas, boxers, chow chows, Doberman pinschers, pit bulls, American Staffordshire bull terriers, rottweilers, and wolf hybrids.1

In the United States, snakes account for 8000 bites per year. These snakes are typically pit viper types, including rattlesnakes, copperheads, cottonmouth water moccasins, and coral snakes. Many of these snake bites occur after hurricanes and floods (eg, Hurricane Katrina) and may be avoided or mitigated with sensible precautions.2

Interestingly, a recent retrospective study by Bhattacharjee et al3 showed that animal bites increase significantly during a full moon. This study, performed in England, tabulated animal bites in the emergency department (ED) on all days of the month, showing this surprising result.

Pathophysiology

The body site on which dog bites occur varies with age; however, the hand is most frequently involved in cat bites.

Snakebites can cause a variety of symptoms, including diarrhea, a burning sensation and pain at the wound site, convulsions, fainting, dizziness, weakness, blurred vision, fever, increased thirst, nausea and vomiting, numbness and tingling, and tachycardia.

Dog bites may cause infections by Staphylococcus, Streptococcus, Eikenella, Pasteurella, Proteus, Klebsiella, Haemophilus, Enterobacter, Capnocytophaga (formerly CDC group DF-2), and Bacteroides species. Cat bites may cause infections by Pasteurella, Actinomyces, Propionibacterium, Bacteroides, Fusobacterium, Clostridium, Wolinella, Peptostreptococcus, Staphylococcus, and Streptococcus species.

Frequency

United States

The incidence of dog bites is 4.7 million people per year in the United States, and the incidence of snake bites is 8000 cases per year. Data collected by the University of Pittsburgh show the median age of persons who sustain dog bites is 15 years, with a significant increase in boys aged 5-9 years.4 While the overall incidence for dog bites is 12.9 cases per 10,000 individuals, the incidence in boys aged 5-9 years is 60 cases per 10,000 individuals.4

Mortality/Morbidity

Annually, in the United States, 10-20 people receive bites that are fatal. Elderly people are more susceptible to animal bites because their ability to fend off attacks is compromised.

Although mortality is rare with most animal bites in the United States, morbidity is common, especially with cat bites infected by Pasteurella species. Dog bites may become infected by Pasteurella species as well.

From 1979 to 1996, 304 people in the United States died from dog bites, according to data from the CDC.

  • In bites by rabid animals, morbidity can result in significant illness. Although bites by rabid dogs comprise 16% of cases, bites by rabid skunks, foxes, and bats comprise most cases. Squirrel bites and hamster bites rarely cause rabies.

  • According to the Humane Society of the United States5, from January 1997 to December 1998, 27 people died from dog bites, 19 of whom were children younger than 12 years and 8 of whom were adults (mostly elderly persons). Most bites are nonfatal, with 230,000 nonfatal bites for every fatal bite.

  • Sepsis can occur in immunocompromised persons with infections caused by Capnocytophaga organisms.

Sex

Males are typically bitten by dogs; usually, young males are most frequently affected. Conversely, women are more frequently bitten by cats than are men.

Age

As a result of their vulnerability and increased possibility of exposure to the animals, individuals who are bitten are usually younger or older persons.



History

Usually, patients with animal bites present to the ED. Occasionally, patients may present to the dermatology office. In either case, inquire about the following:

  • Circumstances leading to the animal bite and disruption of skin integrity

  • Immunization status of the aggressing animal and whether the patient has reason to believe that the animal has rabies

  • Treatment administered up to the time of admission to the ED (Patients may have used folk remedies or performed treatments that may lead to other infections.)

  • Immunization status for tetanus (Immunize patients if their immunizations are not up-to-date.)

Physical

  • Observe the patient with an animal bite for disruption of the skin's integrity. Prescribe antibiotics if disruption of the skin is noted.
  • In patients with snakebites, look for signs of toxicity, including pain, diarrhea, a burning sensation, seizures, syncope, dizziness, blurred vision, hyperhidrosis, fever, increased thirst, loss of coordination, nausea, vomiting, dysesthesias, and tachycardia.
  • If the bite is deep, neurovascular events may have occurred, and injury to tendons and bones must be excluded.
  • Foreign bodies may be observed in the wound.

Causes

Usually, causes of animal bites are related to the possibility of exposure to the animals.

  • Most animal bites involve young children who may play with or inadvertently tease a dog or an animal that attacks the child.
  • Less often, cat bites are associated with severe trauma, but they can result in infection with Pasteurella multocida, thereby causing a significant medical problem.
  • Snakebites occur frequently in campers or hikers in wilderness areas.



Cellulitis

Other Problems to be Considered

Hand infections
Osteomyelitis
Rabies



Lab Studies

  • If infection by P multocida is suspected, perform a Gram stain for the organism, which is a small, gram-negative, ovoid bacillus. Typically, treatment is instituted based on the history of a cat or dog bite.
  • Test for rabies by using the fluorescence antibody method, which assays the viral antigen. Alternatively, analyze a biopsy specimen from the brain of the affected animal.
  • Cultures may be necessary in older wounds and when infection is clinically suggested. Sepsis, although rare, can occur in certain patients.

Imaging Studies

  • If deep wounds occur, radiographs may be necessary to exclude fractures or osteomyelitis in patients presenting after a few days.



Medical Care



  • Treat both dog bites and cat bites with amoxicillin and clavulanate (Augmentin) for 7-10 days, with close follow-up observation of the patient. Alternative treatments include ampicillin and tetracycline; cephalosporins provide lesser benefit than amoxicillin and clavulanate (Augmentin), ampicillin, and tetracycline.

  • If rabies is suspected, typically, the health department is called in to ascertain the status of the animal in question. The local health department can be a significant help in finding out trends in the community and protocols that may be in place for treatment and/or nontreatment of rabies. Updated Infectious Disease Society of America guidelines should be consulted for the most recent recommendations. Until 2004, rabies was considered fatal in unvaccinated individuals. In this year, one individual, Jeana Giese, was treated with a combination of amantadine and ribavirin while in an induced coma. Since this time, other individuals have been treated with this modality, but without success.
    • Postexposure treatment includes administration of rabies immune globulin (RIG) or human diploid cell vaccine (HDCV).

    • HDCV can be administered prior to exposure if people are traveling to endemic areas or working with rabid animals.

    • Animal bites with little or no risk for rabies include bites by squirrels, hamsters, guinea pigs, gerbils, chipmunks, rats, mice, and rabbits.

  • Good wound care is essential for all animal bites. In the ED, irrigate the wound and, if possible, leave it open for healing.

  • Snakebites may require treatment with antivenin if they are serious.

    • Until recently, antivenin was solely derived from horse serum and therefore unable to be administered to patients who are sensitive to horse serum. Now, a newer form called CroFab (Crotalidae Polyvalent Immune Fab), which is an antigen-binding-fragment that is derived from sheep, is available. CroFab is the result of sheep immunized with venom from the Western Diamondback rattlesnake, the Eastern Diamondback rattlesnake, the Mojave rattlesnake, and the cottonmouth water moccasin. It is more effective in studies than the previous equine version.
    • The initial treatment of snakebites involves washing the area of the bite with soap and water, immobilizing the area, keeping the area of the bite below the level of the heart, and monitoring vital signs.

  • Various authorities disagree on whether to suction the area, although all authorities agree that surgical alteration of the area is not appropriate because of the risk of increasing the infection.

Surgical Care

Hand injuries pose a special concern for infection, which may spread into the metacarpophalangeal space; therefore, arrange surgical consultation when appropriate.

Consultations

  • Whether to close the wounds and to what degree surgical cosmesis outweighs the risk of infection are difficult to decide. The questions may be approached best by a multispecialty team, which includes an infectious disease specialist.
  • If the wound has occurred on the hand, advise consultation with a hand surgeon prior to discharge.

Activity

Activity is limited based on the injury. If edema occurs after a dog bite, elevation of the affected area is best; however, in patients with snakebites, do not elevate the affected area to prevent the venom from traveling to the heart.



Amoxicillin and clavulanate (Augmentin) is the drug of choice for the treatment of both dog bites and cat bites. Tetracycline and ampicillin are second-choice drugs. Cephalosporins provide lesser benefit than amoxicillin and clavulanate (Augmentin), ampicillin, and tetracycline. If rabies is diagnosed, administer RIG and HDCV. Serious snakebites are typically treated with antivenin.

Drug Category: Antibiotics

Therapy must be comprehensive, covering all likely pathogens in the context of the clinical setting.

Drug NameAmoxicillin and clavulanate (Augmentin)
DescriptionBroad-spectrum antibiotic that can effectively cover infections caused by Staphylococcus and Pasteurella species. Treats bacterial infection resistant to beta-lactam antibiotics.
In children >3 mo, base dosing protocol on amoxicillin content because of different amoxicillin/clavulanic acid ratios in 250-mg tab (250/125) vs 250-mg chewable tab (250/62.5). Do not use 250-mg tab until child weighs >40 kg.
Adult Dose500/125 mg PO tid or 875/125 mg PO bid
Pediatric Dose10-15 mg/kg PO tid
ContraindicationsDocumented hypersensitivity; history of Augmentin-associated jaundice/hepatic dysfunction
InteractionsCoadministration with warfarin or heparin increases risk of bleeding; may decrease contraceptive effectiveness; concurrent use of allopurinol and amoxicillin associated with increase in frequency of rash due to amoxicillin; may increase toxicity of methotrexate (penicillins may interfere with renal tubular secretion of methotrexate); high penicillin-to-aminoglycoside ratio (greater than 50:1) for prolonged period may result in chemical inactivation of both compounds
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdminister minimum of 10 d to eliminate organisms and to prevent sequelae (eg, endocarditis, rheumatic fever); following treatment, perform cultures to confirm eradication of streptococci; hepatotoxicity may occur; mononucleosis may increase risk for rash; nausea, vomiting, diarrhea may occur; clavulanic acid may cause a false-positive Coombs test result (must be excluded before further testing or treating for immune-mediated hemolytic process)

Drug NameTetracycline (Sumycin)
DescriptionInhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunits. Useful for many skin conditions and is the second-line drug for the treatment of infections caused by P multocida. Unfortunately, staphylococcal coverage is poor; therefore, it is currently a poor choice unless infection with Pasteurella species is the primary concern and the patient is allergic to penicillin.
Adult Dose500 mg PO qid for 10 d
Pediatric Dose<8 years: Not recommended
>8 years: Not established
ContraindicationsDocumented hypersensitivity; severe hepatic dysfunction
InteractionsBioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants
PregnancyD - Unsafe in pregnancy
PrecautionsOccasionally can cause candidal infections in women who are predisposed; photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations during prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines

Drug NameCephalexin (Keflex, Biocef, Keftab)
DescriptionFirst-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Has bactericidal activity against rapidly growing organisms. Has primary activity against skin flora; used for skin infections or prophylaxis in minor procedures.
Although cephalosporins have significant staphylococcal coverage in most populations, coverage of Pasteurella species is not as good as amoxicillin and clavulanate.
Adult Dose500 mg PO qid for 10 d
Pediatric DoseMild-to-moderate infection: 25-50 mg/kg/d PO divided q6h; not to exceed 4 g/d depending on type and severity of infection
Severe infection: 50-100 mg/kg/d PO divided q6h depending on type and severity of infection
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with aminoglycosides increases nephrotoxic potential; cholestyramine may decrease absorption; may increase metformin toxicity;
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy; caution in patients with GI disease (particularly colitis); may result in false-positive reaction for urine glucose using copper-reduction method (eg, Clinitest, Benedict solution, Fehling solution); use urine glucose tests based on enzymatic glucose oxidase reactions (eg, Clinistix, or Tes-Tape) in patients receiving cephalexin therapy

Drug NameCefadroxil (Duricef)
DescriptionFirst-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth.
Adult Dose1-2 g/d PO divided bid
Pediatric Dose<10 kg: 125 mg PO bid for 10 d
10-30 kg: 250 mg PO bid for 10 d
>30 kg: 30 mg/kg/d PO divided bid; not to exceed 2 g/d
ContraindicationsDocumented hypersensitivity; history of gastrointestinal disease, particularly colitis
InteractionsProbenecid may decrease clearance; aminoglycosides and furosemide may decrease nephrotoxicity
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in severe renal insufficiency; high doses may cause CNS toxicity; prolonged use may result in superinfection

Drug NameMoxifloxacin (Avelox, Vigamox)
DescriptionInhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription.
Adult Dose400 mg PO/IV qd
Pediatric DoseNot recommended
ContraindicationsDocumented hypersensitivity; known Q-T prolongation, concurrent administration of drugs that cause Q-T prolongation
InteractionsAntacids and electrolyte supplements reduce absorption; loop diuretics, probenecid, and cimetidine increase serum levels; NSAIDs enhance CNS stimulating effect
May increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT); ferrous sulfate decreases bioavailability (administer moxifloxacin 4 h prior or 8 h following ferrous sulfate); coadministration with drugs that prolong QTc interval (quinidine, procainamide, amiodarone, sotalol, erythromycin, TCAs) increases risk of life-threatening arrhythmia; coadministration with corticosteroids may increase risk of tendon rupture; didanosine, sucralfate, and aluminum- or magnesium-containing antacids may reduce absorption of quinolones
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsIn prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); superinfections may occur with prolonged or repeated antibiotic therapy; fluoroquinolones have induced seizures in persons with CNS disorders and have caused tendinitis or tendon rupture; peripheral neuropathy may occur; prolonged QT interval and torsades de pointes reported; may cause traumatic or nontraumatic tendon rupture; may predispose to seizures or lower seizure threshold; may result in false-positive urine opiate screening

Drug NameErythromycin (Eryc, E.E.S.)
DescriptionRecommended dosing schedule of erythromycin may result in GI upset, causing one to prescribe an alternative macrolide or change to tid dosing. Covers most potential etiologic agents, including Mycoplasma species.
Erythromycin is less active against H influenzae. Although 10 d seems to be a standard course of treatment, treating until the patient has been afebrile for 3-5 d seems a more rational approach. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections.
In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily dose may be taken q12h. For more severe infections, double the dose.
Has the added advantage of being a good anti-inflammatory agent by inhibiting migration of polymorphonuclear leukocytes.
Adult Dose250 mg erythromycin stearate/base (or 400 mg ethylsuccinate) PO q6h, or 500 mg q12h (1 h ac or 2 h pc)
Alternatively, 333 mg PO q8h; increase to 4 g/d depending on severity of infection
Pediatric Dose20-50 mg/kg/d PO divided qid; not to exceed 500 mg/dose
ContraindicationsDocumented hypersensitivity; hepatic impairment
InteractionsCoadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin, increases risk of rhabdomyolysis; decreases metabolism of repaglinide, thus increasing serum levels and effects
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in liver disease; estolate formulation may cause cholestatic jaundice; GI side effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur

Drug Category: Immune globulins

These agents are used with rabies vaccine in individuals previously unvaccinated to provide maximum coverage before immune response to the vaccine occurs.

Drug NameRabies immune globulin (Hyperab, Imogam)
DescriptionProvides passive protection to individuals exposed to rabies virus. Administer approximately half the dose into and around the bite wound as much as possible (given anatomical constraints), and the rest is given intramuscularly at a site remote from the vaccine administration area in the gluteal or deltoid muscle.
Adult Dose20 U/kg IM once after exposure, preferably with first dose of vaccine
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; isolated immunoglobulin A deficiency
InteractionsThrough antigen-antibody antagonism, may diminish antibody response to MMR vaccine; administer live virus vaccines 14-30 d before or 6-12 wk after immune globulin administration; antibody response to rabies vaccine may be delayed if administered simultaneously with rabies immune globulin
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in thrombocytopenia or bleeding disorders; to prevent interference with maximum active immunity from rabies vaccine, not for administration in repeated doses once rabies vaccine treatment initiated

Drug Category: Inactivated viruses

These agents are used for active immunization against rabies.

Drug NameRabies virus vaccine (RabAvert, HDCV, Imovax)
DescriptionInactivated forms of virus that promote immunity by inducing an active immune response. Imovax rabies vaccine ID is for preexposure use only via the intradermal route. Administer ID doses into the deltoid area for postexposure vaccination of adults and older children (for younger children, use the outer aspect of the thigh). Never administer in gluteal area.
Adult DosePreexposure immunization: 1 mL Imovax Rabies Vaccine IM or 0.1 mL Imovax Rabies ID on days 0, 7, and 21-28, then q2-5y depending on antibody titers
Postexposure prophylaxis (patients previously unvaccinated): Administer RIG (20 IU/kg) as soon as possible after exposure and a total of 5 IM doses (do not inject ID) each 1 mL on days 0, 3, 7, 14, and 28
Patients previously immunized: 1 mL IM/ID on days 0 and 3; do not administer RIG
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity
InteractionsHigh-dose corticosteroids or other immunosuppressants (eg, cyclosporine) and radiation therapy may inhibit immunization, causing patients to remain susceptible despite vaccination; avoid use of immunosuppressants during postexposure therapy; persons receiving immunosuppressive therapy should receive RIG IM (3 doses/mL each)
PregnancyC - Safety for use during pregnancy has not been established
PrecautionsInject Imovax Rabies Vaccine only in deltoid area because vaccination may fail if injected into gluteal area; to prevent failure with Imovax Rabies ID, inject ID and not IM; use IM route for Imovax Rabies Vaccine; caution in documented hypersensitivity (may pretreat with antihistamines); epinephrine injection (1:1000), volume replacement, oxygen, and corticosteroids must be available immediately to treat anaphylactic reactions that may occur; carefully consider patient's risk of developing rabies before discontinuing immunization; adverse effects with neural tissue vaccine include anaphylaxis, encephalitis, Guillain-Barré syndrome, meningitis, multiple sclerosis, myelitis, transient paralysis, and retrobulbar neuritis

Drug Category: Antivenom agents

These agents are used to neutralize toxins from snakebites. The physician must be prepared to support the victim's cardiovascular and respiratory systems.

Drug NameCrotalidae polyvalent immune fab-ovine (CroFab)
DescriptionA purified preparation of immunoglobulin fragment obtained from sheep. Rash, urticaria, and pruritus were seen in approximately 33% of patients tested. Although anaphylaxis was not reported in the trials, 1/7th of the patients did develop a serum sickness–like reaction (though this was in the early tests prior to complete purification of the lot).
Adult DoseShould be given within 6 h of initial bite; 4-6 vials IV over 60 min; an additional 4-6 vials may be given 1 h later if status is not improving and/or coagulation studies are worsening; an additional 4-6 vials may be given another 1 h later if signs are again not improved
Maintenance is 2 vials q6h 3 times
Other information available at 87SERPDRUG (877-377-3784)
Pediatric DoseAdminister as in adults
ContraindicationsPrior hypersensitivity to polyvalent crotalid antivenin ovine Fab or any other sheep-derived product; known sensitivity to papain or papaya
InteractionsNone reported
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsHistory of allergic responses or untoward effects after the administration of the standard equine vaccine; a known hypersensitivity to the pineapple-derived enzyme bromelain; a severe venom poisoning (due to lacking clinical data); renal hepatic insufficiency (no pharmokinetic data); copperhead envenomation (because of minimal clinical data); recurrence of symptoms (coagulopathy) may occur after the initial infusion; pregnancy; sensitivity to compounds containing mercury (contains ethyl mercury from thimerosal) thimerosal sensitivity



Further Inpatient Care

  • Inpatient care is reserved for patients with the most severe cases of animal bites, especially severe injuries caused by large animals. Fortunately, it is rarely required for most patients with animal bites.
  • Individuals with rabies pose a significant difference and obviously require care if unvaccinated.

Further Outpatient Care

  • During the healing phase of either a dog bite or a cat bite, a simple infection can easily spread to become a widespread infection. For this reason, monitor the patient for 2-3 days to observe the wound. If the wound continues to heal appropriately, the patient needs little, if any, follow-up care after the antibiotic course is finished.

In/Out Patient Meds

Transfer

  • If the facility does not have specialists for the treatment of facial or neurovascular wounds, transfer the patient to a facility that has specialists in the treatment of these injuries.

Deterrence/Prevention

  • Children should be taught to be cautious around any unknown (and even known) animal. Certain breeds of dog have a higher incidence of biting (eg, collie, boxer, German shepherd), and observation of these breeds is especially needed if young children are playing near or with them.

  • The Web site for The Humane Society of the United States5 has an excellent section on the prevention of animal bites.

  • Administer prophylactic rabies vaccination to spelunkers prior to trips.

  • HDCV can be administered prior to exposure if people are traveling to endemic areas or working with rabid animals.

Complications

  • Most complications involve hand infections, although occasionally, serious infections of other parts of the body affected by animal bites have been reported.

  • Fractures of the skull may be seen in small children if the bite is deep.

  • Rabies is a significant concern if the animal has rabies.

Prognosis

  • In minor bites, the prognosis is excellent.
  • In major bites, the prognosis solely rests on the extent of trauma to the affected organ system.

Patient Education

  • Education plays an important role after the initial visit to the ED because many patients tend to underestimate the need for constant vigilance for infection. Follow-up care is recommended if signs of infection occur despite treatment.

  • For excellent patient education resources, see eMedicine's patient education article Rabies.

  • An excellent website is Dog Bite Law.



Medical/Legal Pitfalls

  • Failure to seek a surgical consultation or an infectious disease consultation in patients with extensive trauma and in patients with hand involvement is a pitfall.

Special Concerns

  • Children are particularly susceptible to bites and trauma, which occur more extensively than in adults.



  1. Leech M. Insuring Is Hard With Dog - Firms Won't Write Policies For Some Pooch Owners. Los Angeles Daily News. August 2, 2002.
  2. North Carolina A&T State University, US Department of Agriculture. Dealing with Snakes After a Storm or Flood. Adapted by P. Bromley from Alabama Cooperative Extension Service. North Carolina State University. Available at http://www.ces.ncsu.edu/disaster/factsheets/pdf/snakes.pdf. Accessed 2002.
  3. Bhattacharjee C, Bradley P, Smith M, Scally AJ, Wilson BJ. Do animals bite more during a full moon? Retrospective observational analysis. BMJ. Dec 23-30 2000;321(7276):1559-61. [Medline].
  4. Weiss HB, Friedman DI, Coben JH. Incidence of dog bite injuries treated in emergency departments. JAMA. Jan 7 1998;279(1):51-3. [Medline].
  5. The Humane Society of the United States. Preventing and Avoiding Dog Bites. 2001. Humane Society. Available at http://www.hsus.org. Accessed July 5, 2001.
  6. Arndt KA, LeBoit PE, Robinson JK. Skin infections caused by unusual bacterial pathogens. In: Cutaneous Medicine and Surgery. Vol 2. Philadelphia, Pa: WB Saunders; 1996:939-48.
  7. Bruce S, Schroeder TL, Ellner K, Rubin H, Williams T, Wolf JE Jr. Armadillo exposure and Hansen's disease: an epidemiologic survey in southern Texas. J Am Acad Dermatol. Aug 2000;43(2 Pt 1):223-8. [Medline].
  8. Cunningham BB, Paller AS, Katz BZ. Rat bite fever in a pet lover. J Am Acad Dermatol. Feb 1998;38(2 Pt 2):330-2. [Medline].
  9. Doud Galli SK, Miller JP. Animal Bites. eMedicine from WebMD [serial online]. August 1, 2006;Available at http://www.emedicine.com/ent/topic725.htm.
  10. Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol. Sep 1997;37(3 Pt 1):365-81; quiz 382-4. [Medline].
  11. Fitzpatrick TB, Eisen AZ, Wolff K. Animal bites, infestations, and insect bites and stings. In: Baker AS, ed. Fitzpatricks Dermatology in General Medicine. Vol 1. New York, NY: McGraw-Hill; 1987:2468-76.
  12. Mayo Foundation for Medical Education and Research. Bites and Stings. December 20, 2000. Mayo Clinic. Available at http://www.mayohealth.org. Accessed July 5, 2001.
  13. Spanierman C. Animal Bites. eMedicine from WebMD [serial online]. March 30, 2006;Available at http://www.emedicine.com/ped/topic107.htm.
  14. Stump J. Bites, Animal. eMedicine from WebMD [serial online]. Februrary 2, 2006;Available at http://www.emedicine.com/emerg/topic60.htm.

Animal Bites excerpt

Article Last Updated: May 25, 2007